HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation

Area of Science:

• Hepatology and Immunology
• Cardiovascular Disease Research
• Transplantation Medicine

Background:

• Hepatitis C virus (HCV) infection increases cardiovascular disease (CVD) risk, particularly post-liver transplantation (LT).
• The precise mechanisms linking HCV to CVD risk after LT remain unclear.
• Endothelial dysfunction is a key factor in CVD development.

Purpose of the Study:

• To investigate the impact of HCV eradication on inflammatory and endothelial activation markers in LT recipients.
• To compare these markers in HCV-infected LT recipients before and after treatment.
• To assess the role of HCV in endothelial dysfunction following LT.

Main Methods:

• Evaluated inflammatory markers (TNF-α, IL-6, IL-8, MCP-1) and endothelial activation markers (E-selectin, ICAM-1, VCAM-1, MMP-9).
• Assessed markers in three groups: LT+/HCV+ (n=45), LT-/HCV+ (n=44), and LT+/HCV- (n=40).
• Measurements were taken before and after HCV eradication in the LT+/HCV+ group.

Main Results:

• LT+/HCV+ patients exhibited higher endothelial activation pre-eradication compared to LT+/HCV- patients.
• HCV eradication significantly decreased ICAM-1 and VCAM-1 levels in both LT+/HCV+ and LT-/HCV+ groups.
• Post-eradication, endothelial activation markers in LT+/HCV+ patients normalized to levels comparable with LT+/HCV- patients.

Conclusions:

• HCV significantly contributes to endothelial dysfunction in liver transplant recipients.
• Eradication of HCV effectively restores endothelial activation, even under immunosuppressive therapy.
• Targeting HCV is crucial for mitigating cardiovascular risk in LT patients.